Drugs Containing Excipient (Inactive Ingredient) BUTYLATED HYDROXYANISOLE

Branded drugs containing BUTYLATED HYDROXYANISOLE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	STROMECTOL	ivermectin	0006-0032	BUTYLATED HYDROXYANISOLE
Merck Sharp & Dohme Corp	ZOCOR	simvastatin	0006-0543	BUTYLATED HYDROXYANISOLE
Allergan Inc	TAZORAC	tazarotene	0023-8335	BUTYLATED HYDROXYANISOLE
Bausch Health US LLC	TARGRETIN	bexarotene	0187-5526	BUTYLATED HYDROXYANISOLE
WALGREENS	ANTI-DIARRHEAL	loperamide hydrochloride	0363-1176	BUTYLATED HYDROXYANISOLE

Generic drugs containing BUTYLATED HYDROXYANISOLE excipient

Company	Ingredient	NDC	Excipient
Merck Sharp & Dohme LLC	ivermectin	0006-0032	BUTYLATED HYDROXYANISOLE
Merck Sharp & Dohme Corp	simvastatin	0006-0543	BUTYLATED HYDROXYANISOLE
Allergan Inc	tazarotene	0023-8335	BUTYLATED HYDROXYANISOLE
Hikma Pharmaceuticals USA Inc.	calcitriol	0054-0007	BUTYLATED HYDROXYANISOLE
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	BUTYLATED HYDROXYANISOLE

Market Dynamics and Financial Trajectory for Butylated Hydroxyanisole (BHA)

Last updated: February 16, 2026

Overview

Butylated hydroxyanisole (BHA) is a synthetic antioxidant used primarily in food, cosmetics, animal feed, and pharmaceuticals to prevent rancidity and oxidative degradation. Its application in pharmaceuticals as an excipient is limited but significant, especially in formulations requiring oxidation stability. The global demand for BHA is driven by food preservation needs, with the pharmaceutical sector gradually increasing its utilization for stabilizing active pharmaceutical ingredients (APIs).

Market Size and Growth

The pharmaceutical excipient segment accounts for a smaller proportion of BHA consumption compared to food and cosmetics. Worldwide, BHA market size was valued at approximately USD 1.8 billion in 2022, with a compound annual growth rate (CAGR) of around 4% from 2018 to 2022.^[1] The pharmaceutical use represents roughly 10-12% of total BHA demand, estimated to be worth USD 200–220 million in 2022.

The growth in pharmaceutical applications hinges on rising R&D activities developing stable formulations for APIs prone to oxidation. This segment is forecasted to grow at a CAGR of roughly 3-5% from 2023 to 2028, driven by increased pharmaceutical manufacturing and exportation from emerging economies.

Key Drivers

• Rising pharmaceutical production: Globally, pharmaceutical sales hit USD 1.4 trillion in 2022, with an annual growth rate of 3-6%, increasing the demand for formulation stabilizers like BHA.
• Development of new drug formulations: As new APIs with oxidation sensitivity are developed, the need for effective antioxidants intensifies.
• Regulatory approval pathways: BHA received approval for direct food additive status and pharmaceutical excipient use in multiple jurisdictions, including the U.S. FDA and European EMA, facilitating market expansion.
• Intensifying focus on product shelf life: Pharmaceutical companies seek excipients that extend shelf life and improve stability, increasing BHA's appeal as a stabilizer.

Regulatory Landscape

BHA’s approval status varies across regions; it is generally classified as Generally Recognized As Safe (GRAS) by the U.S. FDA and authorized in the European Union as a food additive (E320). Its pharmaceutical excipient use is regulated under ICH guidelines and requires adherence to Good Manufacturing Practices (GMP). Regulatory scrutiny concerning carcinogenicity and cumulative exposure has led to tightened limits in some jurisdictions, potentially affecting market size and growth.

Competitive Landscape

Major suppliers include Eastman Chemical, TCI Chemicals, and Sakai Chemical, collectively controlling over 65% of the global BHA supply chain. Innovation focuses on developing BHA derivatives with improved antioxidant efficiency, reduced toxicity, and better regulatory profiles.

Financial Trajectory

• Pricing: BHA pricing in the pharmaceutical excipient segment remains steady, around USD 2.50–3.00 per kg, with slight fluctuations depending on purity and regulatory status.
• Profit margins: Manufacturers report gross margins approximating 15-20%, influenced by raw material costs, regulatory compliance, and R&D investments.
• Investment trends: Due to steady demand, investments in capacity expansion by key suppliers are evident, with several projects announced between 2020 and 2022, estimating a combined USD 50 million CAPEX to meet future demand.

Risks and Challenges

• Regulatory restrictions and potential bans on synthetic antioxidants in food and pharmaceuticals could reduce market size.
• Availability and price volatility of raw materials such as phenol and anisole influence production costs.
• Growing consumer demand for clean-label and natural ingredients may challenge synthetic antioxidant markets.

Outlook

The pharmaceutical excipient segment will experience moderate growth aligned with overall pharmaceutical industry expansion. Regulatory developments will exert significant influence, either constraining or enabling market expansion. Innovation in biodegradable and naturally derived alternatives could pose long-term challenges to BHA's market share in certain regions.

---

Key Takeaways

• BHA’s global market was valued at USD 1.8 billion in 2022, with the pharmaceutical segment representing USD 200–220 million.
• Growth prospects for pharmaceutical application are steady, with a CAGR of 3-5% from 2023 to 2028.
• Major suppliers include Eastman Chemical and Sakai Chemical; innovation targets improved safety and regulatory compliance.
• Pricing remains stable; margins are affected by raw material costs and regulatory factors.
• Regulatory scrutiny could impact future demand, particularly as consumer preferences shift toward natural antioxidants.

---

FAQs

1. What are the primary pharmaceutical applications of BHA?
BHA acts as an antioxidant to stabilize APIs and formulations sensitive to oxidation, thereby extending shelf life and maintaining efficacy.

2. Are there regulatory concerns affecting BHA use in pharmaceuticals?
Yes, while approved by agencies like the FDA and EMA, increased scrutiny and restrictions on synthetic antioxidants could limit its application or lead to stricter limits.

3. How does BHA compare to natural antioxidants in the pharmaceutical sector?
Natural antioxidants like tocopherols and ascorbyl palmitate are gaining attention, but synthetic BHA remains preferred for its cost-effectiveness and efficacy in specific applications.

4. What is the impact of raw material price fluctuations on BHA manufacturing?
Phenol and anisole costs influence BHA prices; supply disruptions or price spikes can squeeze supplier margins.

5. What future developments could influence BHA's market position?
Growing demand for natural antioxidants, regulatory shifts, and advancements in biodegradable stabilizers may alter the landscape.

---

Sources

1. MarketWatch. "Global BHA Market Size, Share & Trends," 2022.